Luc.Cre empty vector Citations (6)

Originally described in: Jacks Lab Unpublished Plasmids
Unpublished

---

Articles Citing Luc.Cre empty vector

Articles
RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LC. Cancer Discov. 2014 Mar;4(3):318-33. doi: 10.1158/2159-8290.CD-13-0346. Epub 2014 Jan 20. PubMed
Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. Herter-Sprie GS, Korideck H, Christensen CL, Herter JM, Rhee K, Berbeco RI, Bennett DG, Akbay EA, Kozono D, Mak RH, Mike Makrigiorgos G, Kimmelman AC, Wong KK. Nat Commun. 2014 Dec 18;5:5870. doi: 10.1038/ncomms6870. PubMed
Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer. Zhong X, Zheng L, Shen J, Zhang D, Xiong M, Zhang Y, He X, Tanyi JL, Yang F, Montone KT, Chen X, Xu C, Xiang AP, Huang Q, Xu X, Zhang L. Mol Cell Biol. 2016 Oct 13;36(21):2742-2754. Print 2016 Nov 1. PubMed
The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. Nowak DG, Katsenelson KC, Watrud KE, Chen M, Mathew G, D'Andrea VD, Lee MF, Swamynathan MM, Casanova-Salas I, Jibilian MC, Buckholtz CL, Ambrico AJ, Pan CH, Wilkinson JE, Newton AC, Trotman LC. J Cell Biol. 2019 Jun 3;218(6):1943-1957. doi: 10.1083/jcb.201902048. Epub 2019 May 15. PubMed
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. Nicholson HE, Tariq Z, Housden BE, Jennings RB, Stransky LA, Perrimon N, Signoretti S, Kaelin WG Jr. Sci Signal. 2019 Oct 1;12(601). pii: 12/601/eaay0482. doi: 10.1126/scisignal.aay0482. PubMed Associated Plasmids pLenti-EF1a-CDK6-mutPAM-PGK-puro pLX304-EV-IRES-GFP pLX304-VHL-IRES-GFP pLX304-VHLdeltaB-IRES-GFP pLX304-VHL-IRES-Tdtomato
The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer. Ji Y, Zhang W, Shen K, Su R, Liu X, Ma Z, Liu B, Hu C, Xue Y, Xin Z, Yang Y, Li A, Jiang Z, Jing N, Zhu HH, Dong L, Zhu Y, Dong B, Pan J, Wang Q, Xue W. Nat Commun. 2023 Nov 28;14(1):7794. doi: 10.1038/s41467-023-43676-3. PubMed

If you have published an article using this material, please email us at to have your article added to this page.